From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...
A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...
From February 12, all newborn babies will be offered screening for spinal muscular atrophy (SMA), a rare progressive neuromuscular disease. SMA will be one of more than 20 other rare disorders ...
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) stock has touched a 52-week low, dipping to $31.24, as investors respond to a ...
Novartis' programme providing free access to its spinal muscular atrophy (SMA ... to market its antisense-based therapy Spinraza (nusinersen) since 2016, while Roche got a green light for its ...
and Tysabri (natalizumab), as well as blockbuster spinal muscular atrophy therapy Spinraza (nusinersen). Biogen will retain its commercial rights to the biosimilars already brought to market ...
In surveys, parents of children with SMA and healthcare professionals in Sweden note the many ways the pandemic affected ...
In a small human trial in SMA patients neurostimulation sessions improved motoneuron function, reduced fatigue, and improved leg muscle strength and walking.
Three people with a muscle-destroying disease destined to worsen got a little stronger when an implanted device zapped their ...
How a tiny spinal implant could help those with muscle-wasting disease - Three people with a muscle-destroying disease got ...
Scholar Rock is asking the U.S. Food and Drug Administration to approve apitegromab for people with spinal muscular atrophy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback